GENSIGHT BIOLOGICS Revenue and Competitors
Estimated Revenue & Valuation
- GENSIGHT BIOLOGICS's estimated annual revenue is currently $11.8M per year.
- GENSIGHT BIOLOGICS's estimated revenue per employee is $155,000
Employee Data
- GENSIGHT BIOLOGICS has 76 Employees.
GENSIGHT BIOLOGICS's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder, CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Marketing | Reveal Email/Phone |
5 | VP, Pharmaceutical Operations | Reveal Email/Phone |
6 | Head Legal Affairs | Reveal Email/Phone |
7 | VP Clinical Operations and Clinical Development | Reveal Email/Phone |
8 | Chief Technology Officer | Reveal Email/Phone |
9 | Director Business Development | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
GENSIGHT BIOLOGICS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is GENSIGHT BIOLOGICS?
N/A
Total Funding
76
Number of Employees
$11.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
GENSIGHT BIOLOGICS News
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing...
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal...
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal...
Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today the success of ...
Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has lau ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.7M | 76 | -3% | N/A |
#2 | $11M | 76 | -20% | N/A |
#3 | $11M | 76 | 1% | N/A |
#4 | $11M | 76 | 4% | N/A |
#5 | $16M | 76 | 19% | $30M |